Neuronetics Inc (STIM)

NASD · Healthcare · Medical Devices · USA

Neuronetics Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Neuronetics delivers transcranial magnetic stimulation treatments through its NeuroStar Advanced Therapy System and operates Greenbrook treatment centers across the United States. The company sells its non-invasive, office-based therapy system and recurring treatment sessions to healthcare providers treating patients with major depressive disorder, obsessive-compulsive disorder, and anxiety.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Neuronetics Inc stock.

Our verdict on STIM

Undervalued: intrinsic value $2.36 per share, market price $1.28, margin of safety 45.9% (as of 2026-11-17).

A 1.4x revenue multiple, discounted for its losses, values the shares at $2.36; the price of $1.28 is 46% below that value.

ETFs with the most weight in STIM

1 more funds hold it; the full list is part of the paid plan.

More on STIM

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than STIM in Medical Devices

Is STIM undervalued or overvalued?

STIM is undervalued (as of the 2026-11-17 close). A 1.4x revenue multiple, discounted for its losses, values the shares at $2.36; the price of $1.28 is 46% below that value.

What is the intrinsic value of STIM?

$2.36 per share (as of the 2026-11-17 close), against a market price of $1.28. That is a margin of safety of 45.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.